Therefore, we performed this population-based study to compare the effectiveness of three neoadjuvant targeted therapy strategies (trastuzumab plus pyrotinib, trastuzumab, or trastuzumab plus pertuzumab) based on the same chemotherapy regimen (docetaxel and carboplatin), which can provide evidence on precise neoadjuvant therapy strategies for patients with HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.